Treatment with lumasiran improved kidney outcomes in patients with primary hyperoxaluria type 1, with no cases of end-stage kidney disease observed during follow-up in a study presented at Kidney Week....
In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...
In the ILLUMINATE-C trial, patients with advanced primary hyperoxaluria type 1 and severe renal impairment treated with lumasiran showed decreased plasma oxalate and good safety profiles at 6 months and 12...
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
Researchers examined a new manifestation of primary hyperoxaluria that has rarely been described in previous literature and reviewed best approaches to managing dental complications in this patient...
Primary hyperoxaluria type 1 is a rare disease that is frequently diagnosed late due to its similar clinical presentation to other types of kidney disease. To better understand the characteristics of...
Individuals with primary hyperoxaluria type 1 are at an increased risk of urinary stone disease, nephrocalcinosis, and chronic kidney disease due to increased hepatic oxalate production. Researchers...
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
